UBS AG Analysts Give Merck KGaA (MRK) a €120.00 Price Target

UBS AG set a €120.00 ($139.53) price target on Merck KGaA (FRA:MRK) in a research report sent to investors on Thursday morning, www.boersen-zeitung.de reports. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other equities analysts also recently weighed in on MRK. Kepler Capital Markets set a €115.00 ($133.72) target price on shares of Merck KGaA and gave the stock a buy rating in a research note on Monday, November 6th. Independent Research GmbH set a €103.00 ($119.77) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Thursday. Berenberg Bank set a €116.00 ($134.88) target price on shares of Merck KGaA and gave the stock a buy rating in a research note on Thursday. J P Morgan Chase & Co set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Wednesday. Finally, equinet AG set a €112.00 ($130.23) price target on shares of Merck KGaA and gave the stock a buy rating in a research note on Friday, November 3rd. Thirteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of €108.61 ($126.29).

Merck KGaA (MRK) opened at €89.79 ($104.41) on Thursday. Merck KGaA has a 12 month low of €89.00 ($103.49) and a 12 month high of €115.00 ($133.72).

COPYRIGHT VIOLATION NOTICE: “UBS AG Analysts Give Merck KGaA (MRK) a €120.00 Price Target” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/11/12/ubs-ag-analysts-give-merck-kgaa-mrk-a-120-00-price-target.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply